Bin Ma

发表

Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.

K. Guckian, T. Macdonald, R. Scannevin, 2010, Bioorganic & medicinal chemistry letters.

Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.

S. Sheikh, T. Bohnert, P. Schroeder, 2020, Journal of medicinal chemistry.

Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators.

I. Enyedy, G. Xiao, B. Lucas, 2019, Bioorganic & medicinal chemistry letters.

Novel Potent Selective Orally Active S1P5 Receptor Antagonists.

K. Guckian, M. Mingueneau, R. Scannevin, 2021, ACS medicinal chemistry letters.

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.

M. Mingueneau, J. Lyssikatos, T. Bohnert, 2021, Journal of medicinal chemistry.

Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors

I. Enyedy, O. Golonzhka, Ti Wang, 2023, ACS chemical neuroscience.

Process Development and Large-Scale Synthesis of BTK Inhibitor BIIB068

S. Ferguson, D. Patience, M. Macphee, 2020 .

Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells

M. Mingueneau, Baohong Zhang, S. Belachew, 2021, Clinical & translational immunology.

ATP-Competitive MLKL Binders Have No Functional Impact on Necroptosis

L. Silvian, J. Salafsky, Ben Moree, 2016, PloS one.